Apathy in Dementia Methylphenidate Trial 2 (ADMET 2) is a Phase III, placebo-controlled,
masked, 6 month, multi-center randomized clinical trial sponsored by National Institutes of
Aging involving 200 participants with Alzheimer's disease (AD). ADMET 2 is designed to
examine the efficacy and safety of methylphenidate as treatment for clinically significant
apathy in AD participants. ADMET 2 will enroll participants from real world settings such as
outpatient, nursing home, and assisted living facilities and will examine the effects of
methylphenidate on apathy and cognition. ADMET 2 will also conduct careful safety monitoring.